The Single-Tablet Regimen ( STaR ) study ( GS-US-264-0110 ) is a 96-week phase 3b study evaluating the safety and efficacy of 2 single-tablet regimens , rilpivirine/emtricitabine/tenofovir DF ( RPV/FTC/TDF ) , and efavirenz/emtricitabine/tenofovir DF ( EFV/FTC/TDF ) in treatment-naive HIV-1-infected subjects .